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Abstract
Background The molecular nature of lipoic acid (LA)
clarifies its capability of taking part to a variety of bio-
chemical reactions where redox state is meaningful. The
pivotal action of LA is the antioxidant activity due to its
ability to scavenge and inactivate free radicals. Further-
more, LA has been shown to chelate toxic metals both
directly and indirectly by its capability to enhance intra-
cellular glutathione (GSH) levels. This last property is due
to its ability to interact with GSH and recycle endogenous
GSH. LA exhibits significant antioxidant activity protect-
ing against oxidative damage in several diseases, including
neurodegenerative disorders. Interestingly, LA is unique
among natural antioxidants for its capability to satisfy a lot
of requirements, making it a potentially highly effective
therapeutic agent for many conditions related with oxida-
tive damage. In particular, there are evidences showing that
LA has therapeutic activity in lowering glucose levels in
diabetic conditions. Similarly, LA supplementation has
multiple beneficial effects on the regression of the mito-
chondrial function and on oxidative stress associated with
several diseases and aging.
Aim The aim of the present review is to describe the
molecular mechanisms underlying the beneficial effects of
LA under various experimental conditions and disease and
how to exploit such effect for clinical purposes.
Conclusion LA has pleiotropic effects in different path-
ways related with several diseases, its use as a potential
therapeutic agent is very promising.
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LA Lipoic acid
DHLA Dihydrolipoic acid
R-LA or (?)LA R-enantiomer lipoic acid
S-LA or (-)LA S-enantiomer lipoic acid
(±)LA Raceme lipoic acid
ROS Reactive oxygen species
RNS Reactive nitrogen species
SOD Superoxide dismutase
GSH Glutathione
GSSG Disulfide form of glutathione
MAPK Mitogen activated protein Kinases
PI3-K Phosphatidyl inositide 3-kinase
aGPC L-a-glycerylphosphorylcholine
GPCR G protein coupled receptor
ERK Extracellular regulated Kinases
JNK c-Jun N-terminal kinase
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AKT The protein kinase B
NF-kB Nuclear factor-KB
IGF-1 Insulin-like growth factor-1
IR Insulin receptor
IRS1 Insulin receptor substrate 1
IRS-1 Insulin receptor substrate-1
AMPK 50 Adenosine monophosphate-activated
protein kinase
PTP1B Cellular protein tyrosine phosphatases
LKB-1 Liver kinase B1
CaMKK Ca/calmodulin dependent protein
kinase
PGC-1-alpha Proliferator activated receptor-gamma
coactivator-1alpha
EAE Experimental autoimmune
encephalomyelitis
AD Alzheimer’s disease
AChE Acetylcholinesterase
AGEs Advanced glycation end product
HNE 4-Hydroxy-2-nonenal
PKC Protein kinase C
GLUT Glucose transport protein
Introduction
Biochemical properties of lipoic acid
Lipoic acid (1,2-dithiolane-3-pentanoic acid; LA) as well
as its reduced form dihydrolipoic acid (DHLA) are com-
pounds having a chiral center (Fig. 1). LA contains two
thiol groups, which may be oxidized or reduced. It is part
of a redox pair, being the oxidized member of the reduced
form dihydrolipoic acid (DHLA) and both the oxidized and
reduced forms of LA are antioxidants. In addition, the
asymmetrical carbon atom, provides special optical
properties.
LA has two enantiomers: the R-enantiomer [R-LA or
(?)LA] and the S-enantiomer [S-LA or (-) LA]. LA is
present in nature as R-enantiomer (Fig. 1), but synthetic
LA is a racemic mixture of (?)LA and (-)LA [(?/-)LA].
Furthermore, both forms have different functions. LA is
also a pivotal component of mitochondrial complex of four
important proteins participating in the synthesis and
degradation of glycine molecule. LA is also a cofactor for
several enzymes including pyruvate dehydrogenase com-
plex (PDC) and a-ketoglutarate dehydrogenase complex
(KDC), two mitochondrial enzymes involved in glucose
metabolism and energy production [27].
In view of its important role in biochemical processes,
LA was enclosed into vitamin B complex, although, now
researchers do not consider it a vitamin. The chemical
activity of LA and DHLA is mainly based in its dithiolane
ring (Fig. 1), in addition, the position of the two sulfur
atoms in the ring creates an exceptionally high electron
density, which confers special properties to LA. It is well
known that in biological systems only the NAD(P)H/
NAD(P)? redox couple has a higher reduction potential.
DHLA—the reduced form of LA—exercises an antioxidant
effect directly by donating electrons to a pro-oxidant or an
oxidized molecule. It can regenerate reduced vitamin C
from dehydroascorbic acid and it can indirectly regenerate
vitamin E back from its oxidized state. Moreover, LA
metabolites have been shown to have anti-inflammatory
and antioxidant effects [37]. However, it has been shown
that LA is able to exert a significant antioxidant effect
through a scavenger activity on free radicals [52], as well
as its capability of LA to chelate metals [19]. Thus, the
chemical nature of LA and DHLA make them capable of
taking part to a variety of biochemical reactions where
redox state is meaningful.
A significant activity of LA is the capability to chelate
toxic metals and also to increase glutathione levels inside
the cells. Glutathione plays important role in the capability
of the system to chelate and discharge a wide variety of
toxins and toxic metals. Several metals known to form
these complexes are manganese, zinc, cadmium, lead,
cobalt, nickel, iron, copper, cadmium, arsenic and mercury.
Antioxidant properties of lipoic acid
Oxidative damage: ROS–RNOS
It is well known that oxidative stress is implicated in the
development and evolution of a lot of diseases and there
are many factors related to oxidative stress as well as to the
development of several pathologies. Reactive oxygen
Fig. 1 Lipoic acid structure: lipoic acid (1,2-dithiolane-3-pentanoic
acid) is an eight-carbon dithiol compound with a high reduction
potential. It has one chiral center that is denoted by an asterisk
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species (ROS) are reactive molecules derived from the
natural byproduct of the oxygen metabolism and having
significant roles in the homeostasis and in the cell-signal-
ing. Nitric oxide (NO) is a soluble and highly diffusible gas
generated by a wide variety of cell types including vascular
endothelial cells [27]. Excess production of endogenous
NO under inflammatory conditions can be toxic to vascular
endothelial cells [54]. Unregulated NO production leads to
an increase in reactive nitrogen species (RNS) resulting in
nitrosative stress (NS), which may give rise to significant
pathological outcomes including cellular injury and dis-
ease. Specifically, NS is involved in the pathogenesis of
low-grade chronic inflammatory-associated diseases such
as atherosclerosis and type 2 diabetes. A better under-
standing of NS-associated underlying mechanisms may
help improve therapeutic outcomes for these diseases [9].
Cell metabolism produces other free radicals from nitrogen
species, called reactive nitrogen species (RNS). ROS and
RNS during physiological conditions have been demon-
strated to be able to mediate a variety of meaningful
functions, such as regulation of signal transduction,
induction of mitogenic response, the involvement on
immune response, etc. ROS are balanced through the
presence of antioxidant groups to take their level invariable
in organisms. These antioxidant systems can be both
enzymatic and non-enzymatic. Breaking the above men-
tioned balance through the over production of ROS as well
as through the reduction of antioxidants, can be deleterious
and it conducts to oxidative stress. Under these conditions,
the unbridled production of free radical induces damage on
cell membrane via lipid peroxidation, modifying signal and
structural proteins to drive to misfolding and aggregation,
and oxidizing RNA/DNA to arrest the transcription and
provoke gene mutation. The bad consequences of the
reactive oxygen species on the cells are: lipid peroxidation,
DNA damage, aminoacids oxidations, etc.
When oxidative stress happens, cells reply to neutralize
the oxidant effects and to restore redox balance by resetting
critical homeostatic parameters. This cellular activity
induces the activation or the silencing of genes encoding
defensive enzymes, transcription factors and structural
proteins. According to the free radical theory of aging,
oxidative stress enhances with increasing age, this condi-
tion brings to cellular dysfunction by accumulation of
oxidation products of lipids, nucleic acids, proteins, etc.
(Fig. 2). When the balance between the production of ROS
and its removal is modified and altered, the cells suffer
oxidative stress. In this field, lipoic acid (LA) has stimu-
lated increasing interest for its the antioxidant and
therapeutic potential.
Mechanisms of protection from oxidative damage
The cells possess innate mechanisms capable to fight free
radicals, neutralizing the consequences and slowing down
the processes of cellular modification and aging. The two
main mechanisms of protection are:
• to remove free radicals through enzymatic activities:
the mitochondrial or cytoplasmic enzymes are ‘‘scav-
engers’’, such as superoxide dismutase (SOD).
• to interact with free radicals giving them the missing
electron and becoming less active as a result of the
antioxidant agents’ activity (vitamins E, A, C, sele-
nium, zinc, glutathione).
Antioxidants are not a homogeneous category of sub-
stances, in fact, they are vitamins, minerals, essential
amino acids. Antioxidants may operate individually or
cooperate protecting each other when they are oxidized. In
addition, each antioxidant is highly specific and can only
interact with one or two free radicals.
It is well known that among the antioxidants of the latest
generation, lipoic acid and DHLA are capable to fulfill the
function of ‘‘scavenger’’ of hydroxyl radicals, hypochlor-
ous acid, of oxygen singlet, and of peroxyl radicals.
Furthermore, they are both chelating iron, copper and other
transition metals responsible for the oxidation of many
substances. Alpha lipoic acid binds these metals to con-
stitute stable complexes. Furthermore, alpha lipoic acid is
capable to prevent the oxidation of ascorbic acid catalyzed
by copper and inhibit lipid peroxidation catalyzed by
copper. In addition, DHLA seems to be capable to regen-
erate other antioxidants such as vitamin E and ascorbic
acid, by their radical forms. As is known that, vitamin E is
the main antioxidant that preserves the membranes which
are the main target of the lipid peroxidation induced by free
radicals.
However, although the peroxyl radicals can be quickly
produced in the membranes, the harmful oxidation of
membrane lipids does not happen as a rule, and the vitamin
E is not depleted rapidly, leading subsequently to a defi-
ciency of vitamin E.
This evident contradiction can be clarified by the
hypothesis of ‘‘recycling’’ of vitamin E, where its antiox-
idant ability is steadily restored by other antioxidants.
Antioxidants that recover vitamin E are vitamin C, the
ubiquinones and thiols. Furthermore, DHLA protects cells
from lipid peroxidation only in the presence of vitamin E or
directly reducing the tocopheryl radical, that is, the vitamin
E in the radical form, or reducing other antioxidants (such
as ascorbic acid) which subsequently regenerate vitamin E.
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Chelation of metals
Under physiological conditions, metal ions such as iron
(Fe), zinc (Zn) and copper (Cu) are meaningful and
indispensable cofactors for normal function of some pro-
teins. The lack or excess of transition metal, however, can
conduct to the progression of several diseases. Zn2? can
cause oxidative stress and mediate neuronal toxicity in
several neurological disorders; Cu and Fe also have the
ability to take part in the production of free radicals under
pathological conditions. Both LA and DHLA well
demonstrated to be able to chelate metal ions by consti-
tuting stable complexes with the ions. Furthermore, LA
was also able to inhibit liposomal peroxidation Cu2? cat-
alyzed [50]. The relevant chelating capability of LA and
DHLA is due to the arrangement of charges on the fatty
acid-like backbone that allows to envelop copper and iron
ions [71]. Regardless of the mechanism, it is clear that LA
possesses a meaningful therapeutic potential in diseases in
which the transition metals mediated cellular toxicity.
In addition, LA and DHLA are also implicated in heavy
metal detoxification. Exposure to heavy metals such as
mercury, lead, cadmium and arsenic has become an
increasingly recognized source of illness worldwide due to
rising levels in air, water and food. Thus, there is growing
interest in locating and utilizing agents that are capable to
chelate these toxic metals for therapeutics strategies [62].
Lipoic acid–glutathione interaction
Glutathione (GSH) is an antioxidant capable to prevent and
avoid injuries and damages to several cellular components,
provoked by reactive oxygen species, such as free radicals,
heavy metals and lipid peroxides. In normal conditions the
90% of the total glutathione stock exists in the reduced
form (GSH) and the 10% exists in the disulfide form
(GSSG). The relationship of reduced glutathione and oxi-
dized glutathione inside the cells is frequently used as a
measurement of oxidative stress as well as cellular toxicity.
Glutathione possesses manifold functions, among which
to be the main endogenous antioxidant produced by the
cells, participating directly to the neutralization of free
radicals and reactive oxygen species, as well as preserving
exogenous antioxidants such as vitamins C and E in the
reduced forms. Another main function of glutathione is to
regulate the nitric oxide cycle. Furthermore, the glutathione
participates to several metabolic and biochemical reac-
tions, such as DNA synthesis and repair, protein synthesis,
amino acid transport and enzyme activation. Moreover, it
has an essential function in iron metabolism. Therefore, the
glutathione activity influences every system in the organ-
ism, particularly the immune system and the nervous
system.
A main property of LA is its interaction with GSH and
its ability to recycle endogenous GSH also. In old rats
where GSH levels were reduced, the intravenous admin-
istration of LA (40 mg/kg body weight) restored tissue
levels of GSH in both the heart and brain [70]. Equally, LA
also enhances GSH levels in T cells, human erythrocytes,
glial cells and lymphocytes [55].
The regeneration of GSH is due to the capability of
DHLA to recycle GSH from GSSG. In addition to gener-
ating GSH by reducing GSSG, LA may also be involved in
the glutathione synthesis. The oxidation–reduction process
of LA to DHLA is an uninterrupted source of cysteine,
which is the rate-limiting amino acid for glutathione pro-
duction [55]. Therefore, the ability of LA to regenerate
GSH is a main mechanism, in addition to being able to
scavenge free radicals and chelate metal ions that may
better clarify its therapeutic efficacy in several pathologies.
Some interesting researches shown that the (?)LA is
more powerful than (-)LA in its ability to stimulate
Fig. 2 Reactive oxygen species
(ROS) generated by endogenous
as well as exogenous sources,
cause damage and accumulation
of proteins, lipids and DNAs,
when defensive (repair)
mechanisms of body become
weak. These ROS also modulate
the signal transduction
pathways. These disturbances
cause organelle damage,
changes in gene expression
followed by altered cellular
responses which ultimately
results into aging
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glucose uptake in L6 myotubes [14], as well as to enhance
insulin-stimulated glucose uptake in obese Zucker rats
[32]. On the other hand, the S-enantiomer exerts a slightly
increased affinity for glutathione reductase [57], thus the
two forms of LA differ in their ability to exercise the
various biological activities.
LA is unique among natural antioxidants in its ability to
fulfill a lot of requirements, making it a potentially highly
effective therapeutic agent for a number of pathological
conditions implicated with oxidative damage.
Summarizing, the antioxidant capacities of LA: to
scavenge reactive oxygen species (ROS); to restore
endogenous antioxidants, such as glutathione, vitamins E
and C; the metal chelating activity, resulting in reduced
ROS production. Some researches showed that LA protects
against oxidative injury in various disease processes,
including neurodegenerative disorders [15, 53]. Despite the
capability of LA to be ‘‘a scavenger of ROS’’ appears to be
responsible, at least partially, of its neuroprotective effects,
it remains unknown whether the neuroprotective effects of
LA may also occur through other mechanisms, such as
induction of the endogenous antioxidants and phase 2
enzymes in neuronal cells. Moreover, the increasing
endogenous defenses might provide defense against
oxidative/electrophilic neuronal cell injury.
Certain researches showed the neuroprotective effects of
LA in neuronal cells. The neuroprotection occurs after
extended pretreatment with LA and is probably due to the
free radical scavenger properties of DHLA endogenously
formed [46]. Some interesting researches assessed the
effect of LA treatment on the expression of some prolif-
eration and differentiation biomarkers of astroglial cells
cultures [6]. The findings highlight the antioxidant and
neuroprotective role played by the (?)LA, indicating the
modulation of biochemical processes correlated with the
proliferation and differentiation of astrocyte cultures [6]. In
particular, the crucial role played by the (?)LA especially
after acute treatment of 24 h in their in vitro model,
denoted that this antioxidant and neuroprotective drug,
operates particularly in proliferating and differentiating
astroglial cell in cultures, as well as, during signaling
transduction mechanism [16].
However, it is also well known that LA mimics insulin
by stimulating glucose uptake in several cell types,
including nerve cells [16]. It is also reported that LA does
not bind to the extracellular domain of the insulin receptor,
but to the tyrosine kinase domain inside the cell. In addi-
tion, LA also modulates MAPK, PI3-K and NFk activities,
which may be independent respect to their activation by
receptor tyrosine kinases [62]. The antioxidant role exer-
cised by LA and its capability in restoring glutathione
content may be related to proliferative and differentiative
state of astrocyte cells, as showed by up and down mod-
ulation of astroglial biomarkers expression assessed [16].
This finding underscores the neuroprotective action
against oxidative stress stimulated by LA.
In addition, since LA exerts a main role as antioxidant
and metabolic component of some enzymatic complexes
involved in glucose metabolism of different cell types, it is
interesting to relate the results obtained by another research
study [22] in which the authors investigated the effect of
both LA alone or in combination with L-a-glycerylphos-
phorylcholine (aGPC) on astroglial cell proliferation and
differentiation in cultures. The results show that the neu-
roprotective action against oxidative stress mimicked by
LA and aGPC. The results show that the neuroprotective
action versus oxidative stress induced by LA and aGPC.
These discoveries may be exploited to better clarify the
antioxidant and metabolic activity played by LA during
astroglial cell proliferation and differentiation, as well as
during an interactive cross-talk among glial and neuronal
cells, after brain injuries or damage correlated with the
oxidative stress.
Molecular pathways
Cellular signaling pathways
A lot of signaling cascades are implicated in oxidative
stress and in the inflammatory reactions. The tyrosine
kinase signaling cascades are activated by various trans-
membrane receptors conducting to the pathogenesis of
allergic airway inflammation [82]. G protein coupled
receptor (GPCR) signaling moderates responses throughout
the immune, nervous, and muscular systems that might
collaborate to the pathogenesis of allergic processes.
The ERK, p38 MAP kinase, JNK, AKT and NF-kB
signaling cascades, control the oxidative stress response,
the inflammatory gene expression, the proliferation and cell
survival [18, 25, 66].
In addition, it is well known that the capability of LA is to
activate various signal transduction pathways and switch on
some transcription factors, indicating that the internalization
of LA may be also mediated by ligand-receptor binding.
Lipoic acid and insulin/IR/Akt pathway
LA performs a lot of functions in the insulin metabolic
pathways, glucose uptake and glycogen synthesis with
several differences between both isomers. For example, it
is well known that R-LA increments the translocation of
GLUT1 and GLUT4 to the plasmatic membrane of adi-
pocytes [44, 67]. Furthermore, these happenings were
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related to the enhanced activity of some proteins from the
insulin signaling pathway, as the insulin receptor (IR), the
insulin receptor substrate 1 (IRS1), the phosphatidyl
inositide 3 kinase (PI3K) and the protein kinase B (AKT).
These occurrences were also observed with some animal
models of insulin-resistance, the known Zucker rats. There
is still a debate in progress if this activity of LA is fully
insulin dependent or not [50, 67]. Moreover, in rat animal
model, LA forestalled the glycogen synthesis and this
action is considered as a pro-oxidant effect [48].
A lot of genes implied in the mediation of cellular stress
resistance are related to the insulin signaling pathway. LA
is similar to the insulin in its activity able to switch on
signaling molecules in the insulin/insulin-like growth fac-
tor-1 (IGF-1) pathway.
A very important enzyme that plays a key role in this
field is the protein kinase B/Akt, that is switched on by the
insulin/IGF-1 pathway.
Anyway, the interaction between LA and the insulin
signaling pathway is now well accepted [15], even if it is
not so obvious what proteins are targets of LA action.
Some research findings in a preadipocyte cell culture,
demonstrated that although Akt became phosphorylated in
response to LA within 30 min, the IR and insulin receptor
substrate-1 (IRS-1) protein were not phosphorylated [8].
However, in adipocytes cell cultures, it was demon-
strated that IR was indeed phosphorylated after LA
treatment, and this was specific to LA and not DHLA [44].
Others researchers also showed that both IRS-1and PI3K
were phosphorylated after following LA treatment [85].
Lipoic acid and phosphatases
Beyond to stimulate the IR, LA seems to be able to stop the
cellular protein tyrosine phosphatases (PTP1B), thereby
interfering with the otherwise inhibitory dephosphorylation
of the IR tyrosine kinase domain [8]. The observed inhi-
bition of PTP1B with H2O2 and LA overlapped with
decreased sulfhydryl content, still suggesting that LA either
directly modified critical thiol groups on this phosphatase
or induced oxidants that did the same. Other phosphatases
may be stopped by LA, which include protein phosphatase-
2A, an important serine/threonine enzyme connected with
the insulin-mediated and other signaling processes [68].
Particularly, there is a growing evidence that (DH)LA,
via its redox nature, modulates significant signal trans-
duction pathways that increase the endogenous cellular
antioxidants (e.g., GSH), lower inflammation (e.g., NF-
kB), and enhance the cell survival opportunities (e.g., IR/
Akt) in times of damage. Induction of kinases and tran-
scription factors or the inhibition of phosphatases include
classic examples of signal amplification that would have
longer term effects than if LA operated only as a transient
oxidant scavenger. Furthermore, basal concentrations of
LA could influence cell-signaling systems, which is con-
sistent with the limited storage of LA in tissues following
its oral administration.
Lipoic acid and nuclear factor kappa B
Lipoic acid has both antioxidant and anti-inflammatory
effects. It is well known that the antioxidant effects are due
to increased antioxidant enzymes, such as glutathione
reductase, restoration of the reduced/oxidized glutathione
ratio, and reduction of NADP? [7].
Oxidative stress associated to inflammation determines
early vascular events correlated to atherogenesis, including
the up modulation of vascular adhesion molecules. These
events require the activation of NF-kB, a transcription
factor inducing the expression of a lot of genes implicated
in the inflammatory processes and endothelial cell migra-
tion. The ROS-mediated inflammation induces activation
of nuclear factor kappa B (NF-jB), activator protein 1 (AP-
1), and mitogen-activated protein kinases (MAPK). NF-jB
at the same time facilitates the production of inflammatory
cytokines: tumoral necrosis factor alpha (TNF-a), inter-
leukin-(IL-) 6, cyclooxygenase 2 (COX-2), and inducible
nitric oxide synthase (iNOS) [60]. Nuclear factor kappa B
(NF-kB) is stored in an inactive form in the cytosol because
of its capacity in binding to an inhibitor kinase of NF-kB
activity, IKK [85]. Oxidative stress is also correlated to
hyperglycemia [13, 14, 26, 84] and the existence of other
conditions such as viral infections, pathogens and radiation
are believed to phosphorylate IkB resulting in its degra-
dation, release and activation of NF-kB. This last one
moves into the nucleus to induce the transcription of sev-
eral molecules correlated to inflammation, vascular
adhesion and migration of monocytes [85].
LA inhibits NF-kB [51] probably because avoid the
degradation of IkB through modulation of upstream kinases
like MAPK [52] or owing to its power to regenerate vita-
min E resulting in inhibition of protein kinase C which is
also able to phosphorylate IkB [4]. This last activity of LA
seems to be independent of its antioxidant action [86].
Therefore, the anti-inflammatory effects of LA are due to
suppression of inflammatory activity from NF-jB, TNF-a
and IL-6 and increased anti-inflammatory proteins, such as
nuclear erythroid 2- related factor (Nrf2) [45].
Lipoic acid and adenosine monophosphatase protein
kinase
LA performs several significative functions in the activity
and expression of 50 adenosine monophosphate-activated
protein kinase (AMPK) in peripheral tissues and in brain
(hypothalamus). AMPK is considered a multifunctional
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protein associated with a lot of intracellular pathways
correlated to metabolism, stress response, cell cycle and
aging [69]. Actually, AMPK performs an important role in
connecting nutritional factors and cancer and is considered
as a hopeful therapeutic target for cancer prevention and
treatment [88].
AMPK is an energy sensor switched on by liver kinase B1
(LKB-1) and Ca/calmodulin dependent protein kinase
(CaMKK). Activation of AMPK arised by down regulation
of transcriptional events that promote synthesis of gluco-
neogenic enzymes, synthesis of fatty acids and up regulation
of metabolic pathways, resulting in ATP production through
glucose and fatty acids oxidation [88].Moreover, AMPKcan
elicit the translocation of GLUT4 to plasma membrane
independent of insulin action [88]. It is still unknown about
the mechanism inducing the activation of AMPK by LA in
peripheral tissues yet [21]. Interesting evidences on the
myoblast cells in culture shows that LA could increase the
activation of AMPK indirectly by the activation of CaMKK
in turn induced by an increment of Ca2? [65]. In fact, the
inhibition of CaMKK removes this last action [65]. Indeed,
these actions of LA-AMPK could also enhance energy
expenditure by increasing the activity of protein kinase-
peroxisome proliferator activated receptor-gamma coacti-
vator-1alpha (PGC-1-alpha) signaling pathway. This last
one is accountable of mitochondrial biogenesis [79]. Every
mentioned behaviors resulting from the activation of AMPK
will provoke a reduction of plasma glucose, an increment of
insulin sensitivity and probably weight loss [69].
Moreover, it has been widely demonstrated the action of
LA on AMPK in insulinoma cells culture and Langerhans
islets. The results of present research study showed a
decrement of insulin secretion by 25–30% at low as well as
at high glucose concentrations [72]. This last evidence was
observed and confirmed with acute and chronic treatment
of LA. Another interesting study showed a protective effect
of LA on 2-deoxy-D-ribose that caused oxidative damage
and insulin expression in cell culture [35]. This protective
activity seems to be correlated to an enhanced intracellular
GSH level. Both studies have showed important details
about the multiple effects of LA upon beta cells. The study
design and the concentration of LA performed in these
experiments could be correlated to the different results
obtained [35]. It is also well known that LA is also capable
to modulate the activity of AMPK in the brain through
metabolic pathways that forbid ATP production such as
oxidative stress, loss of glucose as well as ischemia and
hypoxia [59]. Several studies well reported that hypotha-
lamic AMPK has an important role in the central regulation
of appetite and energy metabolism, as well as reported that
LA performs anti-obesity activity via down regulation of
hypothalamic AMPK activity [34].
Therapeutic potential of lipoic acid
Some pathologies of nervous system, such as Alzhei-
mer’s disease and diabetic polyneuropathy, share
common characteristics: inflammation and oxidative
stress. The inflammatory process related with these
pathologies can stimulate the overproduction of ROS and
NOS. For instance, oxygen and nitrogen radicals gener-
ated by macrophages have been involved as intermediary
of the demyelination and axonal injury in multiple
sclerosis (MS) and its animal model, experimental
autoimmune encephalomyelitis (EAE) [5, 36, 77]. In
addition, studies of oxidative damage show enhancement
of lipid peroxidation, protein and RNA oxidation in
neocortical brain regions in late-stage Alzheimer’s dis-
ease [39].
Furthermore, since oxidative stress cooperates to
develop the disease pathogenesis, it has been investigated
to use LA as a treatment alternative for Alzheimer’s dis-
ease and diabetic polyneuropathy. There is evidence that
LA performs therapeutic activity in diabetic condition
because it is able to induce a lowering glucose levels. In
fact, LA is administered to the patients suffering from
diabetic polyneuropathy—a pathologic condition associ-
ated with increased oxidative stress [20, 76, 91].
Since LA stabilizes the major intracellular antioxidant
system [87], its administration has multiple beneficial
effects on the regression of the mitochondrial function and
on oxidative stress associated with several diseases and
aging. However, appropriate plasma levels need to be
obtained to warrant maximum therapeutic benefit. The use
of the LA as drug or food supplement is interfered by its
rapid metabolism (man plasma half live of 30 min and
bioavailability after oral administration of 30%) and its
stability problems since it is known that LA can poly-
merize. Its degradation in the presence of light was
characterized by a physical change in the compound and a
shift in the ultraviolet spectrum.
Alzhe`imer’s disease
Alzhe`imer’s disease (AD) is a chronic neurodegenerative
disease characterized by the deposition of extracellular
neuritic, b-amyloid peptide containing senile plaques in the
hippocampal area and in the cerebral cortical districts [42].
It is characterized by deprivation of neurons and subse-
quent synaptic damage in the cerebral cortex and
subcortical districts. This damage provokes complete
atrophy and cell degeneration of the affected districts.
The symptoms of inflammation are also clear and evi-
dent around the senile plaques. These plaques start a
cascade of uncontrollable and pathological changes
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conducting to increased levels of extracellular glutamate,
that is in part responsible of the neuronal cell death [80].
At present, the patients affected by mild or moderate
AD, are mainly treated with symptomatic drugs such as
acetylcholinesterase (AChE) inhibitors (donepezil,
rivastigmine and galanthamine) [28]. These drugs reduce
the rapidity at which acetylcholine is broken down and
interact to enhance the concentration of ACh in the brain.
Due to its antioxidant properties and its capability to
modulate various signaling cascades, LA is used as alter-
native therapy for AD. Some investigations ‘‘in vitro and
in vivo’’ provided promising results. In fact, it was
demonstrated that LA represses the advanced glycation end
product (AGEs) induced by lipid peroxidation in neuronal
cell line in vitro [17]. hippocampal neurons in primary
culture were also protected and preserved by DHLA
against amyloid beta-peptide and Fe/H2O2 induced toxicity
[40]. 4-Hydroxy-2-nonenal (HNE) is a highly reactive
product of lipid peroxidation of unsaturated lipids that
induces oxidative toxicity and conducts to neurodegener-
ation. Pretreatment of cortical neurons with LA before
HNE attack caused an enhancement of neuronal cell sur-
vival, an increment of GSH and heat shock protein levels,
as well as the activation of the pro-survival PI3 kinase,
PKC and ERK1/2 signaling pathways [1]. Some research-
ers demonstrated that 1 lM a-lipoate protected rat
hippocampal neurons against glutamate induced cell
damage [46]. In vivo studies in old rats fed a diet supple-
mented with LA for 2 weeks induced a development of
mitochondrial function, an increment of metabolic rate and
a decrement of oxidative damage [24]. In Tg2576 mice, a
transgenic model of cerebral amyloidosis with AD, the LA
uptake improved learning and preservation of memory
[58]. These research findings demonstrate the practicability
of supplementation of lipoic acid to improve the treatment
of AD symptoms. Another interesting study [83] demon-
strated that Ab peptides could significantly inhibit the
proliferation of C6 cells, while LA could reverse the
inhibition effect of Ab and promote the recovery of cell
viability. Ab exposure was also found to decrease the ratio
of GSH and GSSH, and it reduced the expression of both
MnSOD mRNA and protein in the mitochondria of C6
cells. However, LA pretreatment of Ab-treated C6 glioma
cells could reverse the expression changes seen in GSH and
GSSH, increase the ratio of GSH and GSSH, and increase
the expression levels of MnSOD mRNA and protein,
restoring these to approximately control levels. In sum-
mary, the results of the study suggested that Ab exposure
injured C6 cells through oxidative stress and oxidative
damage in the mitochondria, which effect could be
reversed by LA treatment, thereby further suggesting that
LA might protect Ab-treated C6 cells by alleviating
oxidative damage. These results confirmed the
neuroprotective effect of LA and provided evidence of its
mechanism; LA thus might provide a new treatment choice
for neurological degenerative diseases.
Diabetic neuropathy
Diabetic neuropathy (DN) is a frequent and serious com-
plication of both type 1 (DM1) and type 2 (DM2) diabetes.
Diabetic neuropathy is a peripheral nerve dysfunction [60]
as well as a progressive, debilitating condition with a major
impact on patient morbidity, mortality, and quality of life
[56]. DN is a diabetes complication that concerns sensory,
autonomic and motor neurons of the peripheral nervous
system, and it is also the higher source of death rate in
diabetic patients [78]. The first risk factor for DN is
hyperglycemia [64], but the pathology is assigned to
oxidative stress, to the development of advanced glycation
end products, to the uncontrolled activation of protein
kinase C (PKC), that induce an increment of glucose flux
by the polyol pathway and inflammation [11].
Some studies indicated that the enhanced glycemic
control in diabetic patients reduces the risk of diabetic
neuropathy as well as other complications [11].
LA has been administered in patients affected by DN in
Germany for many years (over 30 years) [90]. In the rat
model of streptozotocin-DN-induced, the intraperitoneal
administration of LA improved nerve blood flow as well as
the GSH levels [47].
An interesting study showed that lipid peroxidation was
reduced in both the brain and sciatic nerve [49]. Another
interesting study demonstrated that the treatment with
10 mg LA per kilogram of body weight in some diabetic
rabbits induced a significant reduction of serum glucose
levels [38, 81]. In addition, diabetes induced by reduction
of GSH/GSSG ratio was attenuated and the accumulation
of hydroxyl free radicals was abolished. These studies give
strong and hopeful evidence for the therapeutic potential of
LA in treating symptoms of diabetes and DN.
While much of the work on LA has used animal models
to define its function, there have also been several impor-
tant trials that examine the potential health benefits of LA.
A lot of outcomes concerning the therapeutic administra-
tion of LA in humans lend support to its general role as
antioxidant drug. The best trial for the administration of
LA derived comes from studies on type 2 diabetes [15].
A lot of clinical trials of LA indicated that its oral or
intravenous administration enhances nerve conduction rate
and neuropathic symptoms, such as pain, burning, pares-
thesia and numbness [3, 89]. To date, the therapeutic use of
LA in the treatment of diabetic polyneuropathies represents
the best documented and the most significant benefit of LA
to human health. Furthermore, several experimental evi-
dences support a role for LA as a mitigator of oxidative
D. Tibullo et al.
123
stress in this disease but also for its capability to influence
glucose handling [47]. A number of reports show that LA
improves glucose disposal in diabetic type 2 patients after
administration of LA [30]. Others animal studies show that
LA improves and enhance skeletal muscle glucose uptake
as well as glucose tolerance in the whole-body and it is also
helpful against insulin-resistance [29, 73]. This improved
glycemic treatment induced by LA may be due by its
interaction with regulatory components of the insulin sig-
naling cascade. In fact, LA stimulates the recruitment of
glucose transport protein 4 (GLUT4) since its storage site
in the golgi site towards the sarcolemma. This improves the
glucose uptake by increasing the number of cell surface
GLUT transporters. Evidences derived by cell culture
experiments further supports the role of insulin-mediated
PI3K activity in LA-induced glucose uptake, notably the
sensitivity of this effect on wortmannin—a PI3K inhibitor
[14, 85]. Nevertheless, direct and relevant evidences of the
role played by GLUT4 translocation to improve the glu-
cose disposal via relevant administration of LA are still
indispensable.
Cancer
Oxidative stress possesses also a main role in tumorigen-
esis [12]. LA has been administered as an anticancer agent
mainly in experimental studies of different tumorigenesis
cells type with encouraging results [2, 16, 23, 33, 41, 43].
Until now the molecular mechanisms implicated in this
process are still unknown. In addition to its antioxidant
power, another possibility could be its capability to pro-
voke cellular apoptosis as recently demonstrated in lung
cells [43, 63]. This effects may originated by activation of
caspase proteins induced by endoplasmic reticulum stress
[41].
Another possible hypothesis could be linked to the
cancer cells metabolism, which converts and transforms
preferentially the glucose to lactate, a mechanism known as
the Warburg effect [33]. In fact, LA is the cofactor of
pyruvate dehydrogenase which converts and transforms the
pyruvate molecules to acetyl CoA, resulting in a decrement
in the formation of lactate molecules [16]. The clear and
immediate consequence of this process is the block of the
glycolytic way. In addition, the block of mTOR (target of
rapamycin), a well known signaling pathway involved in
cell growth and correlated to insulin receptor phosphory-
lation- PI3K-AKT activation, has been showed in several
researches using insulinoma cells [72]. This action pro-
voked an inhibition of insulin secretion as well as a
decrement beta-cells growth [72].
Combinations of LA with well known drugs as well as
the synthesis of LA conjugates with other bioactive scaf-
folds are two strategies toward the development of effec-
tive agents for the prevention or treatment of various
disorders and diseases. In agreement to the reviewed
patents, LA can be used in combination therapy, with drugs
(anticancer, antidiabetic, antimicrobial) having synergistic
effects and reduced toxicity [31, 61]. In fact, in some
research studies, LA was administered associated with
other antioxidant agents or with other anticancer drugs
[10]. In this regard, some recent findings [74] well ana-
lyzed the effect of LA on neuroblastoma (NB) cells redox
balance and how such antioxidant effect may impact on NB
cells response to bortezomib (BTZ) drug. In particular, the
data indicated that LA, in combination with BTZ, acted as
chemical chaperone reducing the stress response induced
by proteasome inhibition. Furthermore, these last results
confirmed the neuroprotective effects of LA in neurologi-
cal field, since it acts reducting both redox escalation and
cellular damage induced by BTZ [74, 75].
Concluding remarks
Redox reactions belong to the major metabolic pathways of
the cells. The shift of the balance between pro and
antioxidants can account for mechanisms implicated in
pathogenesis and/or progression of many, apparently
unconnected pathological states, like tumors, neurodegen-
erative diseases, diabetes, etc. This underlines the
importance of antioxidants in the therapy of these diseases.
LA and DHLA have many biological functions involved in
different intracellular systems resulting in a wide range of
actions such as antioxidant protection, chelation of metal
ions, regeneration of other antioxidant agents such as
vitamin C, E and glutathione. Furthermore, LA/DHLA can
also operate in multiple signaling transduction pathways,
such as insulin, nuclear factor kappa B (NF-kB), nitric
oxide synthesis and cellular apoptosis. Also, LA/DHLA
can modulate directly or indirectly the expression of pro-
tein kinase C and AMPK that are both key enzymes in
many downstream systems. It seems that LA is the most
efficient drug of all antioxidants, which is confirmed by the
following data:
• LA is administered orally since it is without difficulty
absorbed in the stomach. LA goes through the blood–
brain barrier and does not show toxic effects and
actions at doses used for prophylactic and therapeutic
purposes.
• A lot of experimental and clinical studies proved
beneficial effect of LA in such diseases as diabetes,
atherosclerosis and heart diseases, cataract and neu-
rodegenerative diseases.
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• Preliminary results on lipoic acid effect on alleviation
of old age-related disorders and adverse influence of
exercise are promising.
Furthermore, studies in vitro and in vivo demonstrated the
wide ability of LA to influence biological functions (Fig. 3).
In addition, as mentioned before, LA and DHLA both act as
antioxidants to directly scavenge ROS and RNOS, chelate
transition and heavy metal ions and mediate the recycling of
other endogenous antioxidants as well as glutathione. LA
alsomodulates various signaling cascades either by receptor-
mediated or non-receptor-mediated processes.
Therefore, the beneficial properties of LA should not be
doubted. However, further studies in the specific diseasemodel
systems are required to set proper dosage regimen as well as its
involvement in cell growth and differentiation processes.
Finally, the studiesdescribedhereinprovidepromisingdata that
can be used as a platform for future endeavors.
Future perspectives
Because LA performs a pleiotropic action on different
pathways linked to the above mentioned diseases, its use as
a potential therapeutic agent is very hopeful.
The activity of LA as a therapeutic agent is corroborated
not only for its actions as a scavenger of ROS/RNS, but
also for its capability to influence signaling cascades. The
stimulation of signal transduction molecules containing
critical cysteine residues may thus prove to be clinically
useful and should be examined in detail in the next future.
One more significant remark for future researches is the
differential outcome of LA administered in vitro and
in vivo. There is still much to learn regarding to the
metabolic destiny of LA and the effects of the various
metabolites on the cells. In fact, it is obvious that LA is
quickly removed from plasma and tissues, whereas
(DH)LA may persist within cell culture media for long
time. This underlines the importance of using in vivo
models to confirm the data obtained in vitro.
Many preclinical efforts on LA should be conducted
keeping in mind these considerations. Finally, this review
had the objective to extend the biochemical and biological
knowledge about LA, even if it is clear that we still need
more knowledge to study in deep about this multifunctional
compound in preclinical phase, before to offer and extend
its use in routine clinical practice.
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